Fluvastatin-induced dermatomyositis;Dermatomyosite induite par la fluvastatine

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 12, 2005, Pages 996-999

  Thual, N ^a   Penven, K ^a   Chevallier, J M ^a   Dompmartin, A ^a   Leroy, D ^a,b  

^a UNIVERSITÉ DE CAEN   (France)

^b CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; FLUINDOSTATIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DYSLIPIDEMIA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; NEOPLASM; RASH; RECURRENT DISEASE;

EID: 31844448099     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(05)79565-X     Document Type: Article

References (22)

1. Dourmishev AL, Dourmishev LA. Dermatomyositis and drugs. Adv Exp Med Biol 1999;455:187-91.
2. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the scandinavian simvastatin survival study. Arch Intern Med 1996;156:2085-92.
3. Thompson PD, Clarckson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
4. Shalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin associated inflammatory myopathy. N Engl J Med 1992;327:649-50.
5. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994;33:199.
6. Hill C, Zeitz C., Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Austr NZ J Med 1995;25:745-6.
7. Hutchinson R. Lovastatin-associated dermatomyositis. Postgrad Med J 1996;72:694
8. Noel B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001;110:670-1.
9. Vasconcelos O, Campbell W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004;30:803-7.
10. Bohan A, Peter JB, Bowman RL Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
11. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985;40:111-8.
12. Lawrence JM, Reckless JPD. Fluvastatin. Expert Opin Pharmacother 2002 ; 3 : 1631-41.
13. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-64.
14. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000;22:441-57.
15. Goldman JA, Fishman AB, Lee JE, Johnson R. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum 1989;32:358-9.
16. Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1.
17. Fauchais AL, Iba Ba J, Maurage P, Kyndt X, Bataille D, Hachulla E, et al. Polymyosites induites ou associées aux traitements hypolipémiants ? À propos de 5 cas. Rev Med Int 2004;25:294-8.
18. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, Toribio E. Severe polymyositis with simvastatin use. Rev Neurol 2003;37:934-6.
19. Kolsi R, Bahloul Z, Hachicha J, Gouiaa R, Jarraya A. Dermatopolymyosite induite par la D-penicillamine au cours de la polyarthrite rhumatoïde. A propos d'un cas avec revue de la littérature. Rev Rhum Mal Osteoartic 1992 ; 59 : 341-4.
20. Vela-Casasempre P, Borras-Blasco J. Alfuzosine-associated dermatomyositis. Br J Rheumatol 1998 ; 37 : 1135-6
21. Evans M, Rees A. Effects of HMG CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25:649-63.
22. Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002;89:231-3.